The canonical generic name for buclatinib is Bugatinib, a second-generation inhibitor that targets ALK, primarily for the treatment of patients with mutations in the ALK gene. Bugatinib is primarily this single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is positive for interstitial lymphoma kinase (ALK). Since this drug is mainly for patients with mutations in the ALK gene, patients need to undergo genetic testing to assess whether they are sensitive to this drug and choose to use it. Brugatinib adverse reactions include interstitial lung disease, hypertension, etc., please strictly follow the doctor’s instructions to use, do not use on their own.